Bionitropin, Human growth hormone, 100 IU, Ampoules 10 ml, 10 pcs

Bionitropin by Bioniche Pharma is a high-purity recombinant human growth hormone (rHGH) formulated with medical glycine (2 mg) and mannitol (22 mg) per vial to stabilize its protein structure. Containing a 191-amino acid peptide identical to naturally occurring human growth hormone, Bioniche Pharma Bionitropin delivers precise biological activity for optimal clinical performance.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

Bionitropin by Bioniche Pharma initiates broad anabolic and metabolic activity by binding directly to transmembrane growth hormone receptors across target tissues. The therapeutic benefits of Bioniche Pharma Bionitropin are primarily driven by stimulated hepatic and peripheral production of Insulin-like Growth Factor-1 (IGF-1):

• Linear & Skeletal Growth: Bioniche Pharma Bionitropin encourages long bone elongation at the epiphyseal plates, stimulates cell division, boosts cellular amino acid uptake, and expands muscle mass, organ size, and red blood cell count. It promotes marked nitrogen retention, leading to reduced blood urea nitrogen (BUN) and lower nitrogen excretion.
• Carbohydrate Metabolism: Treatment with Bionitropin causes a brief initial insulin-like response followed by anti-insulin actions. Higher dosages of Bioniche Pharma Bionitropin reduce peripheral glucose clearance, increase circulating insulin, and can alter glucose tolerance. In growth hormone-deficient pediatric patients presenting with fasting hypoglycemia, Bionitropin helps restore normal blood glucose levels.
• Lipid Metabolism: Bioniche Pharma Bionitropin accelerates lipolysis and the mobilization of stored fatty acids, elevating circulating free fatty acids while noticeably decreasing subcutaneous body fat and overall serum cholesterol.
• Mineral & Connective Tissue Metabolism: Bionitropin supports the retention of sodium, potassium, and inorganic phosphorus, enhances renal phosphate reabsorption, and improves intestinal calcium absorption. Additionally, Bioniche Pharma Bionitropin stimulates collagen and chondroitin sulfate synthesis.

INDICATIONS & CLINICAL USE

• Management of pediatric growth impairment associated with endogenous growth hormone deficiency using Bioniche Pharma Bionitropin.
• Therapeutic administration of Bionitropin for adult growth hormone deficiency resulting from hypothalamic-pituitary trauma, surgery, or radiotherapy.
• Clinical application of Bioniche Pharma Bionitropin in treating HIV-related muscle wasting (cachexia) and short bowel syndrome.
• Supportive management in Turners syndrome, non-GHD short stature, or chronic renal disease under specialized medical oversight.

CONTRAINDICATIONS

• Active proliferative or preproliferative diabetic retinopathy.
• Active oncological conditions or growing intracranial tumors; malignancies must be inactive with treatment finalized prior to initiating Bioniche Pharma Bionitropin therapy.
• Acute critical illness stemming from complications of open-heart surgery, major abdominal procedures, severe multi-trauma, or acute respiratory distress.
• Prader-Willi syndrome in pediatric patients presenting with severe obesity or compromised respiratory function.
• Known hypersensitivity to somatropin, excipients, or reconstituting solvents used with Bionitropin by Bioniche Pharma.

PRECAUTIONS & CLINICAL MONITORS

• Glucose Tolerance & Insulin Sensitivity: Due to the anti-insulin effects of Bioniche Pharma Bionitropin, individuals with diabetes or impaired glucose tolerance require frequent blood sugar testing and potential anti-diabetic medication adjustments.
• Thyroid & Adrenal Function: Therapy with Bionitropin by Bioniche Pharma can accelerate peripheral conversion of T4 to T3 or unmask central hypothyroidism, requiring routine thyroid (free T4, TSH) and adrenal monitoring.
• Epiphyseal Closure Monitoring: Pediatric patients undergoing Bioniche Pharma Bionitropin treatment should be regularly evaluated by a pediatric endocrinologist and discontinue therapy upon complete epiphyseal fusion.

ADVERSE REACTIONS

• Metabolic & Fluid Balance: Mild fluid retention, peripheral edema, joint stiffness, arthralgia, myalgia, and temporary carpal tunnel symptoms associated with Bioniche Pharma Bionitropin administration.
• Endocrine & Dermatological: Altered glucose tolerance, elevated blood sugar, and localized lipoatrophy or lipohypertrophy at the injection site (mitigated by rotating Bionitropin injection locations).
• Rare & Severe: Benign intracranial hypertension (pseudotumor cerebri) marked by severe headache, visual changes, nausea, and vomiting.

DOSAGE & RECONSTITUTION DIRECTIONS

Bioniche Pharma Bionitropin is formulated for subcutaneous or intramuscular administration following proper reconstitution with bacteriostatic or sterile water:

• Dosing Protocol: Individualize Bionitropin dosing based on patient weight, body surface area, diagnosis, and serum IGF-1 levels under strict medical supervision.
• Reconstitution Technique: Slowly stream the diluent along the inner glass wall of the Bioniche Pharma Bionitropin vial. Gently swirl in a smooth circular motion until completely dissolved; do not shake vigorously to prevent peptide degradation.

STORAGE & HANDLING

• Unreconstituted Lyophilized Powder: Store Bioniche Pharma Bionitropin under refrigeration at +2°C to +8°C (+36°F to +46°F). Unopened vials remain stable at room temperature (up to 25°C) for up to 1 month without loss of biological activity.
• Reconstituted Solution: After reconstituting Bionitropin with bacteriostatic water, keep refrigerated at +2°C to +8°C and use within 14 days, protected from direct light. Do not freeze. Keep strictly out of reach and sight of children.